Helus Pharma Unveils New HLP003 Data at Psych Congress 2026
Event summary
- Helus Pharma presented four posters on HLP003 at Psych Congress 2026, including 12-month efficacy data from a Phase 1/2a study.
- The Phase 3 PARADIGM program evaluating HLP003 as an adjunctive treatment for MDD was also detailed.
- HLP003 has received Breakthrough Therapy Designation from the FDA.
- Helus Pharma is also developing HLP004 for generalized anxiety disorder.
The big picture
Helus Pharma's presentation of new HLP003 data at Psych Congress 2026 underscores the growing interest in psychedelic-assisted therapies for mental health conditions. The Phase 3 PARADIGM program is a critical step in validating HLP003 as an adjunctive treatment for MDD, a market with significant unmet needs. The company's focus on serotonergic agonists positions it within a broader industry shift towards neuroplasticity-promoting treatments.
What we're watching
- Clinical Progress
- The pace at which HLP003 advances through Phase 3 trials will determine its market potential.
- Regulatory Pathway
- Whether the Breakthrough Therapy Designation accelerates FDA approval for HLP003.
- Competitive Landscape
- How Helus Pharma differentiates HLP003 in the growing psychedelic-assisted therapy market.